The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: (WFRF:(Tsao Ming Sound)) pers:(Botling Johan) > (2021) > The International A...

1 av 1
Föregående post
Nästa post
Till träfflistan

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

Mino-Kenudson, Mari (författare): Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 122, Boston, MA 02114 USA.;Harvard Med Sch, 55 Fruit St,Warren 122, Boston, MA 02114 USA.

Le Stang, Nolwenn (författare): Ctr Leon Berard Unicanc, Lyon, France.

Daigneault, Jillian B. (författare): Int Assoc Study Lung Canc, Denver, CO USA.

visa fler...

Nicholson, Andrew G. (författare): Royal Brompton & Harefield Natl Hlth Serv NHS Fdn, London, England.;Imperial Coll London, Natl Heart & Lung Inst, London, England.

Cooper, Wendy A. (författare): Royal Prince Alfred Hosp, New South Wales NSW Hlth Pathol, Camperdown, NSW, Australia.;Univ Sydney, Camperdown, NSW, Australia.

Roden, Anja C. (författare): Mayo Clin, Dept Pathol, Rochester, MN USA.

Moreira, Andre L. (författare): New York Univ Langone Hlth, Dept Pathol, New York, NY USA.

Thunnissen, Erik (författare): Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.

Papotti, Mauro (författare): Univ Turin, Anat Pathol, Turin, Italy.

Pelosi, Giuseppe (författare): Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.;Ist Ricovero & Cura Carattere Sci IRCCS MultiMed, Milan, Italy.

Motoi, Noriko (författare): Natl Canc Ctr, Diagnost Pathol, Tokyo, Japan.

Poleri, Claudia (författare): Off Pathol Consultants, Buenos Aires, DF, Argentina.

Brambilla, Elisabeth (författare): Univ Grenoble Alpes, Grenoble, France.

Redman, Mary (författare): Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.

Jain, Deepali (författare): All India Inst Med Sci, New Delhi, India.

Dacic, Sanja (författare): Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA.

Yatabe, Yasushi (författare): Natl Canc Ctr, Diagnost Pathol, Tokyo, Japan.

Tsao, Ming Sound (författare): Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.

Lopez-Rios, Fernando (författare): HM Hosp, Pathol Lab Dianas Terapeut, Madrid, Spain.

Botling, Johan (författare): Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk och experimentell patologi,Johan Botling

Chen, Gang (författare): Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.

Chou, Teh-Ying (författare): Taipei Vet Gen Hosp, Taipei, Taiwan.

Hirsch, Fred R. (författare): Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA.;Mt Sinai Hlth Syst, Ichan Sch Med, New York, NY USA.

Beasley, Mary Beth (författare): Mt Sinai Hlth Syst, Ichan Sch Med, New York, NY USA.

Borczuk, Alain (författare): Weill Cornell Med, Dept Pathol, New York, NY USA.

Bubendorf, Lukas (författare): Univ Basel, Inst Pathol, Basel, Switzerland.

Chung, Jin-Haeng (författare): Seoul Natl Univ, Bundang Hosp, Seoul, South Korea.

Hwang, David (författare): Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.

Lin, Dongmei (författare): Peking Univ Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China.

Longshore, John (författare): Carolinas Pathol Grp, Charlotte, NC USA.

Noguchi, Masayuki (författare): Univ Tsukuba, Tsukuba, Ibaraki, Japan.

Rekhtman, Natasha (författare): Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.

Sholl, Lynette (författare): Harvard Med Sch, 55 Fruit St,Warren 122, Boston, MA 02114 USA.;Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.

Travis, William (författare): Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.

Yoshida, Akihiko (författare): Natl Canc Ctr, Diagnost Pathol, Tokyo, Japan.

Wynes, Murry W. (författare): Int Assoc Study Lung Canc, Denver, CO USA.

Wistuba, Ignacio I. (författare): Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.

Kerr, Keith M. (författare): Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland.

Lantuejoul, Sylvie (författare): Ctr Leon Berard Unicanc, Lyon, France.

visa färre...

Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 122, Boston, MA 02114 USA;Harvard Med Sch, 55 Fruit St,Warren 122, Boston, MA 02114 USA. Ctr Leon Berard Unicanc, Lyon, France. (creator_code:org_t)

Elsevier, 2021
2021
Engelska.
Ingår i: Journal of Thoracic Oncology. - : Elsevier. - 1556-0864 .- 1556-1380. ; 16:4, s. 686-696

Relaterad länk:: https://urn.kb.se/re...; visa fler...; https://doi.org/10.1...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide and for several other indications depending on the country. Four assays have been approved/Communaute Europeene-In vitro Diagnostic (CV-IVD)-marked, but PD-L1 IHC seems diversely implemented across regions and laboratories with the application of laboratory-developed tests (LDTs).Method: To assess the practice of PD-L1 IHC and identify issues and disparities, the International Association for the Study of Lung Cancer Pathology Committee conducted a global survey for pathologists from January to May 2019, comprising multiple questions on preanalytical, analytical, and postanalytical conditions.Result: A total of 344 pathologists from 64 countries participated with 41% from Europe, 24% from North America, and 18% from Asia. Besides biopsies and resections, cellblocks were used by 75% of the participants and smears by 11%. The clone 22C3 was most often used (69%) followed by SP263 (51%). They were applied as an LDT by 40% and 30% of the users, respectively, and 76% of the participants developed at least one LDT. Half of the participants reported a turnaround time of less than or equal to 2 days, whereas 13% reported that of greater than or equal to 5 days. In addition, quality assurance (QA), formal training for scoring, and standardized reporting were not implemented by 18%, 16%, and 14% of the participants, respectively.Conclusions: Heterogeneity in PD-L1 testing is marked across regions and laboratories in terms of antibody clones, IHC assays, samples, turnaround times, and QA measures. The lack of QA, formal training, and standardized reporting stated by a considerable minority identifies a need for additional QA measures and training opportunities.

Hitta via bibliotek

Journal of Thoracic Oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Klinisk laborato ...

Artiklar i publikationen: Journal of Thora ...

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub